07:52 AM EDT, 09/19/2024 (MT Newswires) -- Tonix Pharmaceuticals Holding ( TNXP ) said Thursday it received a patent from the US Patent and Trademark Office for its intranasal migraine treatment, Tosymra.

The patent granted on Tuesday covers the pharmaceutical composition, treatment method, and delivery system for Tosymra, the company said. The patent is set to expire in 2030, excluding potential extensions, it added.

Shares of the company rose over 7% in recent premarket activity.

Price: 0.1565, Change: +0.01, Percent Change: +7.86